Multi-targeting of New Biologic Drugs

George Wang, Ph.D.
VP of Discovery and Preclinical Service

November 22nd, 2023





Stock Code: 2269.HK

Disclaimer




All rights are reserved. The information in this PPT shall not be considered as information disclosure or investment advice.

This document is strictly confidential to the recipient only, and may not be copied, reproduced, redistributed, disseminated, or used or disclosed to any other person, or published, in whole or in part, for any other purpose without written permission from the Company and the author.

This document has been prepared using information provided by the Company but without further investigation cannot be warranted as to its accuracy or completeness. Certain data in this document was obtained from external data sources, and the Company has not verified such data with independent sources. Accordingly, the Company makes no representations as to the accuracy or completeness of that data. Such data involves risks and uncertainties and is subject to change based on various factors. The use of registered trademarks, commercial trademarks and logos or photographic materials within this document are exclusively for illustrative purposes and are not meant to violate the rights of the creators and/or applicable intellectual property laws.

Multi-targeting as new wave of innovative drugs






MULTISPECIFIC DRUGS HERALD A NEW ERA OF BIOPHARMACEUTICAL INNOVATION

Raymond J. Deshaies. Nature 2020


Multi-specific/functional Antibody Drugs Approved in Recent Years





Antibody as Building Block Multi-targeting Biologics





Two Screening Funnels of Innovative Biologic Drugs



Functionality

Specificity
Epitope

- Cross-reactivity
- Homologue
- Paralogue

Biochemical assays

Cellular assays


Rodent PK

Cyno PK

PD models

Efficacy models

Toxicity



Developability

Expression level
Purity
Solubility
PTM & Stress Test
Physical Stability

- Colloidal Stability
- Thermal Stability
- Freeze-ThawStability

Serum Stability
Preliminary Scalable
Manufacturability
Preliminary Formulation
Ability
Immunogenicity Risk

WuXi Biologics' Discovery Service from Concept to IND





Target Evaluation

Oncology, Immunology Metabolic Disease, Neurology Rare Disease, Ophthalmology etc.

Antibody Generation

Single B Cloning
Phage Displayed VHH, scFv, Fab libraries
Hybridoma (OMT, Alloy etc.)

Complex Biologics

Bispecific Antibodies
Antibody Drug Conjugates
Immune Cell Engagers
Fusion Proteins, Immunocytokines

IND Candidate

Developability/CMC Dev Cyno PK/GLP Tox Study Design IND Filing Package

Reagent Generation

Antigen Design
Tool Cell Line Engineering
Protein Generation & Analytics

Lead Optimization

Humanization
Affinity Maturation
Developability Improvement
Other Protein Engineering


In vitro/In vivo

Molecular/Biochemical/Cellular Assays
PK & PD Models
Efficacy Models
Exploratory Toxicology Models

Confidential

Enable Clients Advancing Projects to Clinical Development & Approval





Thank You

www.wuxibiologics.com/discovery

info@wuxibiologics.com

Learn More



